Eledon Competitors

Stocks . USA . 
Stock . Eledon Pharmaceuticals
ELDN Stock  USD 2.09  0.04  1.88%   
Eledon Pharmaceuticals competes with Puma Biotechnology, Abeona Therapeutics, Allogene Therapeutics, Vanda Pharmaceuticals, and Atea Pharmaceuticals; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Eledon Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Eledon Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Eledon Pharmaceuticals Correlation with its peers.
To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.

Eledon Pharmaceuticals vs Editas Medicine Correlation

Very good diversification

The correlation between Eledon Pharmaceuticals and EDIT is -0.35 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Eledon Pharmaceuticals and EDIT in the same portfolio, assuming nothing else is changed.

Moving against Eledon Stock

  0.79KURA Kura OncologyPairCorr
  0.72ABP Abpro Holdings Buyout TrendPairCorr
  0.68DWTX Dogwood TherapeuticsPairCorr
  0.53LYRA Lyra TherapeuticsPairCorr
  0.49GNLX Genelux CommonPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Eledon Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.102.096.75
Details
Intrinsic
Valuation
LowRealHigh
0.081.656.31
Details

Eledon Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Eledon Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Eledon and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Eledon Pharmaceuticals does not affect the price movement of the other competitor.

High positive correlations

VNDA
+ 0.86
PBYI
AVIR
+ 0.84
PBYI
ALLO
+ 0.8
PBYI
EDIT
+ 0.8
VYGR
VNDA
+ 0.78
ABEO
TRDA
+ 0.77
ABEO
  

High negative correlations

EDIT
- 0.78
PBYI
EDIT
- 0.76
VNDA
HUMA
- 0.75
VNDA
EDIT
- 0.74
AVIR
HUMA
- 0.72
PBYI
EDIT
- 0.7
ALLO

Risk-Adjusted Indicators

There is a big difference between Eledon Stock performing well and Eledon Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Eledon Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
PBYI  2.72  0.50  0.10  1.07  4.19 
(3.08)
 5.25 
(3.92)
 43.28 
ABEO  2.85  0.15  0.06  0.16  3.23 
(3.08)
 6.16 
(5.48)
 26.76 
ALLO  4.11  0.76  0.14  5.03  4.11 
(5.46)
 12.38 
(7.48)
 26.97 
VNDA  3.75  0.97  0.20 (1.68) 3.73 
(4.28)
 11.39 
(5.84)
 39.51 
AVIR  2.29  0.37  0.09  0.59  3.16 
(2.36)
 5.54 
(4.43)
 17.79 
VYGR  2.39 (0.27) 0.00 (0.16) 0.00 
 0.00 
 4.58 
(5.23)
 19.71 
TRDA  2.91  0.67  0.22  1.00  2.62 
(3.60)
 6.65 
(4.08)
 18.48 
HUMA  4.38 (0.50) 0.00 (0.14) 0.00 
 0.00 
 8.93 
(8.13)
 21.58 
ACHV  3.24 (0.33) 0.00 (0.04) 0.00 
 0.00 
 7.19 
(6.18)
 25.05 
EDIT  3.34 (0.76) 0.00 (0.26) 0.00 
 0.00 
 7.54 
(8.18)
 26.68 

Eledon Pharmaceuticals Competitive Analysis

The better you understand Eledon Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Eledon Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Eledon Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ELDN PBYI ABEO ALLO VNDA AVIR VYGR TRDA HUMA ACHV
 1.88 
 2.09 
Eledon
 3.92 
 6.61 
Puma
 0.19 
 5.12 
Abeona
 3.68 
 1.69 
Allogene
 1.20 
 7.42 
Vanda
 0.48 
 4.16 
Atea
 0.27 
 3.70 
Voyager
 2.56 
 10.82 
Entrada
 13.93 
 1.05 
Humacyte
 0.69 
 4.36 
Achieve
Market Volatility
(90 Days Market Risk)
Dangerous
Somewhat reliable
Somewhat reliable
Very risky
Slightly risky
Moderately volatile
Slightly risky
Somewhat reliable
Very risky
Slightly risky
Market Performance
(90 Days Performance)
Soft
Solid
Weak
Fair
Good
Fair
Weakest
Good
Weak
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Low
Strong
High
Low
Small
Small
Low
Risky
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Hold
Strong Buy
Strong Buy
Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Hold
Cautious Hold
Cautious Hold
Strong Sell
Strong Hold
Hold
Buy
Cautious Hold
Cautious Hold
Current Ratio
22.22
2.04
2.21
11.42
5.62
27.46
1.55
14.05
17.46
5.81
Net Asset
177.41 M
213.33 M
108.93 M
548.71 M
656.2 M
464.67 M
393.05 M
526.32 M
137.87 M
38.63 M
Profit Margin
N/A
0.17
205.88
N/A
-0.4
N/A
N/A
-1.68
N/A
N/A
EBITDA
(35.39 M)
48.08 M
(56.62 M)
(243.33 M)
(32.53 M)
(131.8 M)
(78.56 M)
50.78 M
(132.23 M)
(37.42 M)
Current Valuation
81.31 M
294.11 M
71.36 M
204.73 M
165.12 M
(4.82 M)
191.67 M
128.39 M
242.9 M
192.61 M
Price To Book
4.92
3.01
1.63
1.2
0.96
1.02
0.94
1.18
70.17
6.87
Operating Margin
N/A
0.18
-208.02
N/A
-0.56
N/A
-2.29
-29.15
-32.39
N/A
Retained Earnings
(355.59 M)
(1.31 B)
(813.26 M)
(1.82 B)
(174.29 M)
(364.22 M)
(326.18 M)
(129.34 M)
(686.01 M)
(205.58 M)
Current Asset
N/A
223.55 M
31.95 M
418.72 M
166.55 M
97.88 M
195.89 M
N/A
N/A
22.54 M
Beta
0.89
1.23
1.13
0.6
0.58
0.23
1.33
-0.12
1.92
1.84
Number Of Employees
31
172
136
226
368
56
172
183
218
25
Shares Outstanding
79.63 M
50.39 M
54.19 M
224.73 M
59.1 M
78.13 M
55.6 M
38.22 M
193 M
53.23 M
Cash Flow From Operations
(47.27 M)
38.92 M
(56.02 M)
(200.3 M)
(15.76 M)
(135.5 M)
(15.31 M)
(41.56 M)
(98.12 M)
(29.77 M)
Total Debt
954 K
74.08 M
23.05 M
90.76 M
12.36 M
1.64 M
43.73 M
59.21 M
16.54 M
9.96 M
Return On Equity
-0.95
0.4
0.76
-0.54
-0.17
-0.38
-0.46
-0.27
-2.5
-1.61
Return On Asset
-0.44
0.099
-0.3
-0.27
-0.12
-0.24
-0.25
-0.16
-0.63
-0.65
Number Of Shares Shorted
6.32 M
3.59 M
13.82 M
18.63 M
2.88 M
7.3 M
3.45 M
896.14 K
37.15 M
6.82 M
Book Value Per Share
1.52
2.29
3.27
1.41
7.89
4.04
3.96
9.5
-0.03
0.64
Current Liabilities
N/A
32.44 M
6.51 M
26.36 M
51.32 M
6.25 M
23.93 M
N/A
N/A
9.1 M
Total Asset
177.41 M
213.33 M
108.93 M
548.71 M
656.2 M
464.67 M
393.05 M
526.32 M
137.87 M
38.63 M
Debt To Equity
0.003
5.19
0.42
0.13
0.022
0.005
0.4
0.12
0.36
1.18
Short Ratio
7.14
9.67
12.56
4.72
1.01
18.82
6.8
4.37
6.94
11.02
Target Price
8.0
5.0
20.64
7.38
13.63
7.67
15.0
18.0
7.71
15.38
Shares Owned By Institutions
56.9
71.22
66.92
63.59
74.73
72.42
56.46
78.34
25.01
41.14
Market Capitalization
174.39 M
333.09 M
278 M
379.79 M
443.82 M
323.44 M
206.28 M
403.21 M
235.46 M
230.5 M
Price To Earnings To Growth
0.01
0.03
N/A
-4.18
-2.42
N/A
N/A
N/A
N/A
N/A
Price To Earning
N/A
18.52
0.11
-3.3
24.83
15.03
5.62
N/A
18.04
-0.03
Price To Sales
N/A
1.57
695.0
11631.14
2.09
1.9
6.59
6.55
149.88
N/A
Net Income
(36.18 M)
30.28 M
(63.73 M)
(257.59 M)
(18.9 M)
(168.38 M)
(65 M)
65.63 M
(148.7 M)
(39.83 M)
Earnings Per Share
-1.3
0.71
1.21
-0.98
-1.44
-1.77
-2.17
-2.57
-0.27
-1.35
Shares Owned By Insiders
1.08
15.38
11.07
16.64
7.21
13.6
16.12
12.23
16.36
4.36
Revenue
N/A
230.47 M
N/A
22 K
198.77 M
N/A
80 M
210.78 M
N/A
N/A
Working Capital
132.15 M
51.55 M
84.27 M
267.86 M
338.91 M
443.75 M
227.02 M
400.56 M
27.91 M
29.79 M
Cash And Equivalents
70.46 M
77.96 M
20.1 M
490.49 M
440.86 M
684.48 M
148.06 M
244.25 M
189.04 M
29.38 M
Cash Per Share
5.12
1.71
3.38
3.41
7.79
8.22
3.83
7.81
1.84
3.03
Gross Profit
N/A
163.04 M
(29.28 M)
(166.49 M)
200.27 M
(120.09 M)
(102.99 M)
(80.2 M)
(73.8 M)
N/A
Day Typical Price
2.11
6.73
5.16
1.67
7.48
4.17
3.75
10.78
1.13
4.37
Accumulation Distribution
22358.89
18062.98
25357.5
0.0585
26818.4
16765.44
29614.8
21740.15
2.6 M
17551.49
Market Facilitation Index
N/A
0.0
N/A
0.1
N/A
N/A
0.0
0.0
N/A
N/A
Daily Balance Of Power
(0.36)
(0.69)
(0.06)
0.6
(0.31)
0.1111
(0.04)
0.2308
(0.68)
0.1579
Period Momentum Indicator
(0.04)
(0.27)
(0.01)
0.06
(0.09)
0.02
(0.01)
0.27
(0.17)
0.03
Rate Of Daily Change
0.98
0.96
1.0
1.04
0.99
1.0
1.0
1.03
0.86
1.01
Day Median Price
2.12
6.79
5.18
1.66
7.51
4.17
3.78
10.77
1.17
4.38
Price Action Indicator
(0.04)
(0.31)
(0.06)
0.06
(0.13)
N/A
(0.09)
0.19
(0.20)
N/A
Coefficient Of Variation
1718.91
852.12
1250.33
700.84
622.06
789.3
(1,983)
492.5
(2,065)
(4,601)
Mean Deviation
3.47
2.72
2.85
4.11
3.75
2.29
2.39
2.91
4.38
3.24
Jensen Alpha
0.0315
0.4955
0.1491
0.762
0.9743
0.368
(0.27)
0.6691
(0.50)
(0.33)
Total Risk Alpha
(0.22)
0.0559
(0.10)
0.207
0.326
0.0712
(0.51)
0.3537
(0.96)
(0.55)
Sortino Ratio
0.036
0.0965
0.0628
0.1354
0.1964
0.0915
N/A
0.217
N/A
N/A
Downside Variance
24.63
22.15
13.12
26.13
18.56
14.25
N/A
8.9
N/A
N/A
Standard Deviation
4.66
4.66
4.0
5.5
5.84
3.46
3.27
3.64
6.28
4.34
Kurtosis
0.3824
13.07
5.34
0.7958
6.36
4.56
2.69
0.2171
7.36
1.91
Potential Upside
8.97
5.25
6.16
12.38
11.39
5.54
4.58
6.65
8.93
7.19
Treynor Ratio
0.094
1.07
0.1591
5.03
(1.68)
0.5884
(0.16)
0.9954
(0.14)
(0.04)
Maximum Drawdown
20.18
43.28
26.76
26.97
39.51
17.79
19.71
18.48
21.58
25.05
Variance
21.75
21.71
16.03
30.24
34.1
11.96
10.69
13.27
39.45
18.81
Market Risk Adjusted Performance
0.104
1.08
0.1691
5.04
(1.67)
0.5984
(0.15)
1.01
(0.13)
(0.03)
Risk Adjusted Performance
0.0549
0.1022
0.072
0.1228
0.1373
0.1091
(0.03)
0.1704
(0.03)
(0.01)
Skewness
0.2196
0.0972
1.29
0.5129
1.72
0.1219
0.8711
0.2764
1.76
0.4955
Semi Deviation
4.17
4.19
3.23
4.11
3.73
3.16
N/A
2.62
N/A
N/A
Information Ratio
0.0383
0.0975
0.0568
0.1258
0.1449
0.0999
(0.08)
0.1776
(0.06)
(0.04)
Value At Risk
(7.32)
(3.92)
(5.48)
(7.48)
(5.84)
(4.43)
(5.23)
(4.08)
(8.13)
(6.18)
Expected Short fall
(4.05)
(3.08)
(3.08)
(5.46)
(4.28)
(2.36)
N/A
(3.60)
N/A
N/A
Downside Deviation
4.96
4.71
3.62
5.11
4.31
3.78
N/A
2.98
N/A
N/A
Semi Variance
17.42
17.57
10.41
16.87
13.91
10.01
N/A
6.87
N/A
N/A

Eledon Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Eledon Pharmaceuticals Competition

Eledon Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Eledon Pharmaceuticals in relation to its competition. Eledon Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Eledon Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Eledon Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Eledon Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Eledon Pharmaceuticals position

In addition to having Eledon Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Artificial Intelligence Thematic Idea Now

Artificial Intelligence
Artificial Intelligence Theme
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Eledon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eledon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eledon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eledon Pharmaceuticals Stock:
How To Invest In Eledon
Details
Is Eledon Stock a good investment?
Details
What is Eledon Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Eledon Pharmaceuticals Correlation with its peers.
To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Will Biotechnology sector continue expanding? Could Eledon diversify its offerings? Factors like these will boost the valuation of Eledon Pharmaceuticals. Projected growth potential of Eledon fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Eledon Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Eledon Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Eledon's accounting equity. The concept of intrinsic value - what Eledon Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Eledon Pharmaceuticals' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between Eledon Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Eledon Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Eledon Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY